REGULATORY

FY2014 NHI Revision Sees Price Cut of 5.64% without Tax Surcharges, 1,118 Long-Listed Products Subject to New Rule

March 5, 2014

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s NHI drug prices will be pared by an average of 5.64% on a drug spending basis (1.22% on a medical spending basis) in the drug price revision in April, factoring out adjustments tied to the sales tax hike that…

To read the full story

Market Share of Generics Stood at 46.9% Based on New Calculation Method as of September Last Year: MHLW
March 6, 2014
Januvia/Glactiv to See 10.1% Price Cut Due to Re-Pricing Following Market Expansion
March 6, 2014
Pfizer No. 1 Premium Getter in FY2014 Revision, Non-Japanese Makers Sweep Top 10 List
March 5, 2014

REGULATORY

Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026
MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use

By Takashi Ebisawa

International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…